Pfizer Inc. confirmed the received marketing approval by the EC for LITFULO™ (ritlecitinib) aimed for the treatment of severe alopecia areata in adults and adolescents aged 12 years and above.
This article summarized the latest R&D progress of Etonogestrel, the Mechanism of Action for Etonogestrel, and the drug target R&D trends for Etonogestrel.
This article summarized the latest R&D progress of Estradiol valerate, the Mechanism of Action for Estradiol valerate, and the drug target R&D trends for Estradiol valerate.
Heidelberg Pharma AG announced it began patient recruitment for the fifth group in the Phase I/IIa trial of their main development candidate, HDP-101, with a dose of 100 µg/kg.
This article summarized the latest R&D progress of Brompheniramine maleate, the Mechanism of Action for Brompheniramine maleate, and the drug target R&D trends for Brompheniramine maleate.